Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Quetiapine for Cocaine Use and Cravings
- Conditions
- Substance-Related DisordersCocaine-Related Disorders
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2024-04-19
- Target Recruit Count
- 42
- Registration Number
- NCT00232336
- Locations
- 🇺🇸
VA Puget Sound Health Care System, American Lake Division, Tacoma, Washington, United States
Quetiapine for the Treatment of Insomnia in Alzheimer's Disease
- Conditions
- Alzheimer's DiseaseInsomnia
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2009-05-05
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 18
- Registration Number
- NCT00232570
- Locations
- 🇺🇸
Fletcher Allen Health Care-Clinical Neuroscience Research Unit, Burlington, Vermont, United States
Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia
- Conditions
- Smoking Behavior in Schizophrenia
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2006-10-17
- Lead Sponsor
- Arthur P. Noyes Research Foundation
- Target Recruit Count
- 40
- Registration Number
- NCT00231101
- Locations
- 🇺🇸
Arthur P. Noyes Research Foundation, Norristown, Pennsylvania, United States
A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder
- Conditions
- Bipolar I Disorder
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 30
- Registration Number
- NCT00232414
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
A Study of Quetiapine for the Treatment of Mood Disorders in Adolescents
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 20
- Registration Number
- NCT00221468
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Quetiapine in Social Anxiety Disorder
- Conditions
- Social Anxiety Disorder
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-12-19
- Lead Sponsor
- Duke University
- Target Recruit Count
- 15
- Registration Number
- NCT00215254
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Comparative Study of New Medications for Psychosis in Adolescents
- Conditions
- Psychotic DisordersSchizophreniaSchizophreniform DisordersSchizoaffective Disorders
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT00222495
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence
- Conditions
- Cocaine DependenceBipolar Disorder
- Interventions
- Drug: PLaceboDrug: Quetiapine
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00223210
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 115
- Registration Number
- NCT00223249
- Locations
- 🇺🇸
The UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- SchizophreniaPsychotic Disorders
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 753
- Registration Number
- NCT00216476
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.